The growing ecosystem of companies involved in the leverage of AI technologies on health care and drug development needs a new evaluation scheme, more complicated than the typical evaluation schemes for startups in other sectors
Old Evaluation Systems Are Inadequate For AI Health Care And Drug Development Ecosystem
